Active Ingredient(s): Durvalumab
FDA Approved: * May 1, 2017
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Imfinzi Overview

Durvalumab[4] (trade name Imfinzi) is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca.[5] It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279). Durvalumab is known as a checkpoint inhibitor drug.[6] Contents 1 Medical uses 2 Clinical trials 2.1 MYSTIC 2.2 PACIFIC 2.3 CASPIAN 3 References 4 External lin...

Read more Imfinzi Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Imfinzi Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 50mg/ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Imfinzi: (2 results)

Sorted by National Drug Code
  • 0310-4500 Imfinzi 120 mg/2.4ml Intravenous Injection, Solution by Astrazeneca Pharmaceuticals Lp
  • 0310-4611 Imfinzi 500 mg/10ml Intravenous Injection, Solution by Astrazeneca Pharmaceuticals Lp

Other drugs which contain Durvalumab or a similar ingredient: (1 result)